- Home
- SHMD vs ANVS Comparison
SHMD vs ANVS Comparison
Compare SHMD & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | ANVS |
|---|---|---|
| Founded | 1864 | 2008 |
| Country | Germany | United States |
| Employees | 676 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.4M | 69.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SHMD | ANVS |
|---|---|---|
| Price | $7.70 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $1.54 |
| 52 Week High | $10.65 | $5.50 |
Technical Indicators
Market Signals| Indicator | SHMD | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 62.03 | 55.41 |
| Support Level | $5.29 | $1.92 |
| Resistance Level | $9.55 | $2.38 |
| Average True Range (ATR) | 0.69 | 0.17 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 75.43 | 69.40 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.